164 related articles for article (PubMed ID: 21401607)
21. Ameliorative potential of montelukast on ischemia-reperfusion injury induced vasculitic neuropathic pain in rat.
Muthuraman A; Ramesh M; Sood S
Life Sci; 2012 May; 90(19-20):755-62. PubMed ID: 22483690
[TBL] [Abstract][Full Text] [Related]
22. Combination drug therapy using edaravone and Daio-Orengedoku-to after transient focal ischemia in rats.
Cho KH; Oh JK; Jang YS; Jung JW; Oh HR; Park EK; Kim DH; Moon SK; Kim DH; Ryu JH
Methods Find Exp Clin Pharmacol; 2008; 30(6):443-50. PubMed ID: 18850045
[TBL] [Abstract][Full Text] [Related]
23. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney.
Otunctemur A; Ozbek E; Cekmen M; Cakir SS; Dursun M; Polat EC; Somay A; Ozbay N
Ren Fail; 2013; 35(3):403-10. PubMed ID: 23342977
[TBL] [Abstract][Full Text] [Related]
25. [An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia].
Wei EQ; Zhu CY; Xu QQ; Yu YP; Zhu YF; Zheng MZ
Sheng Li Xue Bao; 2003 Dec; 55(6):742-7. PubMed ID: 14695495
[TBL] [Abstract][Full Text] [Related]
26. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
Hoxha M; Rovati GE; Cavanillas AB
Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
[TBL] [Abstract][Full Text] [Related]
27. Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat.
Lieber G; Jimenez J; Hunter JC; McLeod RL; Jia Y
Pharmacology; 2010; 85(5):311-8. PubMed ID: 20453555
[TBL] [Abstract][Full Text] [Related]
28. Montelukast reduces ischaemia/reperfusion-induced bladder dysfunction and oxidant damage in the rat.
Sener G; Sehirli O; Toklu H; Ercan F; Alican I
J Pharm Pharmacol; 2007 Jun; 59(6):837-42. PubMed ID: 17637175
[TBL] [Abstract][Full Text] [Related]
29. Montelukast reduces seizures in pentylenetetrazol-kindled mice.
Fleck J; Temp FR; Marafiga JR; Jesse AC; Milanesi LH; Rambo LM; Mello CF
Braz J Med Biol Res; 2016; 49(4):e5031. PubMed ID: 26909785
[TBL] [Abstract][Full Text] [Related]
30. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
31. [Pharma-clinics. Medication of the month. Montelukast (Singulair)].
Louis R
Rev Med Liege; 2001 Jun; 56(6):460-2. PubMed ID: 11496728
[TBL] [Abstract][Full Text] [Related]
32. A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis.
Okubo K; Baba K
Allergol Int; 2008 Dec; 57(4):383-90. PubMed ID: 18946234
[TBL] [Abstract][Full Text] [Related]
33. Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors.
Singh P; Sharma B
Curr Neurovasc Res; 2016; 13(1):10-21. PubMed ID: 26500103
[TBL] [Abstract][Full Text] [Related]
34. ONO-1078 reduces NMDA-induced brain injury and vascular cell adhesion molecule-1 expression in rats.
Zhang LH; Wei EQ
Acta Pharmacol Sin; 2005 Apr; 26(4):435-40. PubMed ID: 15780192
[TBL] [Abstract][Full Text] [Related]
35. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
[TBL] [Abstract][Full Text] [Related]
36. Montelukast prevents ischaemia/reperfusion-induced ovarian damage in rats.
Akdemir A; Erbaş O; Ergenoğlu M; Ozgür Yeniel A; Oltulu F; Yavaşoğlu A; Taskiran D
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():71-6. PubMed ID: 24360058
[TBL] [Abstract][Full Text] [Related]
37. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice.
Yu GL; Wei EQ; Wang ML; Zhang WP; Zhang SH; Weng JQ; Chu LS; Fang SH; Zhou Y; Chen Z; Zhang Q; Zhang LH
Brain Res; 2005 Aug; 1053(1-2):116-25. PubMed ID: 16051204
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast.
Shiota N; Shimoura K; Okunishi H
Eur J Pharmacol; 2006 Oct; 548(1-3):158-66. PubMed ID: 16949072
[TBL] [Abstract][Full Text] [Related]
39. Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats.
Daglar G; Karaca T; Yuksek YN; Gozalan U; Akbiyik F; Sokmensuer C; Gurel B; Kama NA
J Surg Res; 2009 May; 153(1):31-8. PubMed ID: 18656901
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats.
Kalonia H; Kumar P; Kumar A; Nehru B
Neuroscience; 2010 Nov; 171(1):284-99. PubMed ID: 20813166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
